JPRN-jRCTs041180113已完成2 期
A Multicenter single arm Phase II clinical trial of the second-line treatment with FOLFIRI plus panitumumab after failure of the first-line treatment with FOLFOX plus panitumumab for advanced and/or recurrent RAS wild-type colorectal cancer with special reference to the changes in biomarker expression examined by a liquid biopsy and its effect on the refractory tumor - PBP
agata Naoki0 个研究点目标入组 54 人开始时间: 2019年3月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
For entire patients of the present study, protocol treatment did not demonstrate our expected efficacy. However, observed 6-month PFS rate and median PFS may suggest continuous use of panitumumab in combination with FOLFIRI after panitumumab and FOLFOX treatment can be considered for RAS/BRAF wild type mCRC proved by liquid biopsy, especially when patients discarded the first-line treatment due to intolerance of FOLFOX, or when vascular endothelial growth factor inhibitors cannot be utilized.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Histologically-confirmed inoperable colorectal adenocarcinoma excluding vermiform appendix cancer and anal canal cancer
- •2)Refractory tumor with measurable disease by RECIST 1.1 that has progressed, or appearance of evaluable new lesion after the first line therapy with FOLFOX+panitumumab
- •3)Age >=20 years at the time of informed consent
- •4)ECOG performance status (PS) of 0-2
- •5)Written informed consent prior to study-specific screening procedures
- •6)Life expectancy of at least 90 days
- •7)Withdrawal from the first-line chemotherapy with FOLFOX + panitumumab for RAS wild-type advanced or metastatic colorectal cancer due to intolerable toxicity excluding to panitumumab alone or progressive disease
- •8)Adequate organ function according to following laboratory values obtained within 14 days before enrollment (excluding patients who received blood transfusions or hematopoietic growth factors within 14 days before the laboratory test)
- •i)Neutrophil count:>=1500/mm3
- •ii) Platelet count: >=10.0 x 104/mm3
- •iii) Hemoglobin: >=8.0 g/dL
- •iv) Total bilirubin: <=1.5 mg/dL
- •v) AST, ALT: <=100 IU/L (<=200 IU/I if liver metastases present)
- •vi) Serum creatinine: <=1.5 mg/dL
- •9)Confirmed RAS wild type tumor at the time of the first-line therapy
排除标准
- •1)History of other malignancy with a disease-free interval <5 years (other than curatively treated cutaneous basal cell carcinoma, curatively treated carcinoma in situ of the cervix, and gastroenterological cancer confirmed to be cured by endoscopic mucosal resection)
- •2)With massive pleural effusion or ascites requiring intervention
- •3)Radiological evidence of brain tumor or brain metastases
- •4)Active infection including hepatitis
- •5)Any of the following complication:
- •i) Gastrointestinal bleeding or gastrointestinal obstruction (including paralytic ileus)
- •ii) Symptomatic heart disease (including unstable angina, myocardial infarction, and heart failure)
- •iii) Interstitial pneumonia or pulmonary fibrosis
- •iv) Uncontrolled diabetes mellitus
- •v) Uncontrolled diarrhea (that interferes with daily activities despite adequate therapy)
- •6)Any of the following medical history:
- •i) Myocardial infarction: History of one episode within one year before enrollment or two or more lifetime episodes
- •ii) Serious hypersensitivity to any of the study drugs
- •iii) History of adverse reaction to fluoropyrimidines suggesting dihydropyrimidine dehydrogenase (DPD) deficiency
- •7)Previous treatment with irinotecan hydrochloride
- •8)Current treatment with atazanavir sulfate
- •9)Previous treatment with tegafur, gimeracil, and oteracil potassium within seven days before enrollment
- •10)Pregnant and lactating females, and males and females unwilling to use contraception
- •11)Requires continuous treatment with systemic steroids
- •12)Psychiatric disability that would preclude study compliance
- •13)Otherwise determined by the investigator to be unsuitable for participation in the study
研究者
相似试验
招募中
不适用
A Multicenter single arm Phase II clinical trial of the second-line treatment with FOLFIRI plus panitumumab after failure of the first-line treatment with FOLFOX plus panitumumab for advanced and/or recurrent RAS wild-type colorectal cancer with special reference to the changes in biomarker expression examined by a liquid biopsy and its effect on the refractory tumorcolorectal cancerJPRN-UMIN000026817PO Epidemiological and Clinical Research Information Network(ECRIN)55
招募中
2 期
A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma.bone cancer10040778chondrosarcomaNL-OMON47217eids Universitair Medisch Centrum23
进行中（未招募）
1 期
Clinical study testing the combination of sirolimus and cyclophosphamiodein chondrosarcoma and myxoid liposarcoma patientsEUCTR2013-005155-32-NLeiden University Medical Center108
进行中（未招募）
1 期
Clinical study testing the combination of sirolimus and cyclophosphamiodein chondrosarcoma and myxoid liposarcoma patientsConventional chondrosarcomaMyxoid liposarcoma with PIK3CA mutation or PTEN lossMesenchymal or dedifferentiated chondrosarcomaEUCTR2013-005155-32-ESGrupo Español de Investigación en Sarcomas (GEIS)
进行中（未招募）
1 期
Olaparib and Pegylated Liposomal Doxorubicin for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tube Cancer patients.Platinum resistant ovarian primary peritoneal carcinoma, and fallopian tube cancer patients.MedDRA version: 20.0Level: PTClassification code 10070908Term: Ovarian cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004850-14-ESGrupo Español de Investigación en Cancer de Ovario32